---
document_datetime: 2026-01-23 17:47:58
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/ronapreve-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: ronapreve-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 5.2446027
conversion_datetime: 2026-01-26 20:23:14.426603
docling_version:
  docling-serve: 1.10.0
  docling-jobkit: 1.8.1
  docling: 2.70.0
  docling-core: 2.60.2
  docling-ibm-models: 3.11.0
  docling-parse: 4.7.3
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

Medicinal product no longer authorised

2 A Commission decision(CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CDisissuedwithintwomonths of the opinionforvariationsfalling underthescope ofArticle23.1a(a)ofRegulation(EU)No.712/2012,orwithin oneyearforotherprocedures.

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

<div style=\"page-break-after: always\"></div>

product (including batch release or quality

## Medicinal product no longer authorised